modelS01EE03
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Bimatoprost | |
| ATC code: | S01EE03 | route: | ophthalmic |
| compartments: | 1 | |
| dosage: | 0.03 | mg |
| volume of distribution: | 0.67 | L |
| clearance: | 1.5 | L/hr/kg |
| other parameters in model implementation | ||
Bimatoprost is a synthetic prostamide analog used primarily to reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It is approved for ophthalmic use and is widely prescribed today.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult volunteers following topical ocular administration.
References
Goldberg, I, et al., & Bejanian, M (2014). Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial. The British journal of ophthalmology 98(7) 926–931. DOI:10.1136/bjophthalmol-2013-304064 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24667994
Day, DG, et al., & Bejanian, M (2013). Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial. The British journal of ophthalmology 97(8) 989–993. DOI:10.1136/bjophthalmol-2012-303040 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23743437
DuBiner, HB, & Hubatsch, DA (2014). Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial. BMC ophthalmology 14 151–None. DOI:10.1186/1471-2415-14-151 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25432143
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)